Active Pharmaceutical Ingredient– tag –
-
Lonza Expands Commercial ADC Payload-Linker Manufacturing Capacity at Visp to Support Growing Oncology Pipeline
BioPharma APAC Switzerland Overview CDMO giant Lonza has announced significant expansion plans for its commercial antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp, Switzerland, site. This strategic investme... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
Asahi Kasei’s Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar API Manufacturing Facility to Reduce Pharmaceutical Manufacturing Time for Thermolabile Peptides and Oligonucleotides, Advancing Towards GMP Production
Asahi Kasei Japan Overview Asahi Kasei has implemented a novel forward osmosis–membrane distillation (FO-MD) system at Peptistar's API manufacturing facility to shorten production times for thermolabile APIs like peptides and oligonucleo... -
Codexis Pioneers Enzymatic RNA Manufacturing to Scale Beyond Solid-Phase Synthesis, Meeting Demand Exceeding 30 Metric Tons of Oligonucleotide API Annually
Codexis USA Overview Codexis is advancing enzymatic RNA manufacturing to overcome limitations of traditional solid-phase oligonucleotide synthesis (SPOS), significantly enhancing scalability and product quality for RNA therapeutics. This... -
CordenPharma Announces Multi-Million Dollar Expansion of Oligonucleotide Manufacturing to Meet Soaring Demand for Nucleic Acid-Based Medicines
Pharmaceutical Technology Europe Overview CordenPharma announced a multi-million dollar investment to significantly expand its oligonucleotide manufacturing capacity across its global network. This strategic expansion aims to meet the in... -
Synthetic Small Molecule API Market to See Growth through 2035, Driven by Oncology Pipeline and Generic Demand, Report Says
IndexBox Global Overview This article provides an overview of a market research report published by IndexBox, which forecasts growth in the global synthetic small molecule API market, driven by increasing chronic disease prevalence, a ro... -
U.S. Small Molecule API Market Forecast to Reach USD 103.37 Billion by 2035, Driven by HPAPI and Domestic Manufacturing
Precedence Research USA Overview This article presents an overview of a market research report published by Precedence Research, which projects the U.S. small molecule API market to reach USD 103.37 billion by 2035. Key growth drivers in... -
Silexion Therapeutics Initiates GMP Manufacturing for KRAS-Driven Cancer siRNA Therapy SIL204, Secures Phase 2/3 Trial Approval
Manila Times (via GlobeNewswire) ケイマン諸島 Overview Silexion Therapeutics has commenced GMP clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic targeting mutated KRAS oncogenes. Concurrently, the company rec... -
Divi’s Labs: The ‘TSMC of Pharma’ for Peptides? GLP-1 Demand Elevates Manufacturing to Strategic Imperative
Antifragile Thinking Global Overview The surging global demand for GLP-1 therapeutics has transformed peptide manufacturing into one of the most strategically critical areas within the CDMO sector. India's Divi's Labs stands out as a key... -
Small Molecule Drug CDMO Market Sees Strong Growth, Driven by HPAPI and Continuous Manufacturing; WuXi AppTec Leads
OpenPR Global Overview The small molecule drug CDMO market is experiencing robust growth, fueled by increased outsourcing from pharmaceutical and biotech companies. Key drivers include investments in specialized facilities for highly pot...
12